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Background: Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin
K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic
VTE; their use could avoid parenteral treatment and/or laboratory monitoring of anticoagulant effects.
Methods: A prespecified pooled analysis of the EINSTEIN-DVT and EINSTEIN-PE studies compared the efficacy and
safety of rivaroxaban (15 mg twice-daily for 21 days, followed by 20 mg once-daily) with standard-therapy (enoxaparin
1.0 mg/kg twice-daily and warfarin or acenocoumarol). Patients were treated for 3, 6, or 12 months and followed for
suspected recurrent VTE and bleeding. The prespecified noninferiority margin was 1.75.
Results: A total of 8282 patients were enrolled; 4151 received rivaroxaban and 4131 received standard-therapy. The
primary efficacy outcome occurred in 86 (2.1%) rivaroxaban-treated patients compared with 95 (2.3%) standard-therapy
-treated patients (hazard ratio, 0.89; 95% confidence interval [CI], 0.66–1.19; pnoninferiority < 0.001). Major bleeding was
observed in 40 (1.0%) and 72 (1.7%) patients in the rivaroxaban and standard-therapy groups, respectively (hazard ratio,
0.54; 95% CI, 0.37–0.79; p = 0.002). In key subgroups, including fragile patients, cancer patients, patients presenting with
large clots, and those with a history of recurrent VTE, the efficacy and safety of rivaroxaban were similar compared with
standard-therapy.
Conclusion: The single-drug approach with rivaroxaban resulted in similar efficacy to standard-therapy and was
associated with a significantly lower rate of major bleeding. Efficacy and safety results were consistent among key
patient subgroups.
Trial registration: EINSTEIN-PE: ClinicalTrials.gov, NCT00439777; EINSTEIN-DVT: ClinicalTrials.gov, NCT00440193.
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Venous thromboembolism (VTE), the collective term
for deep-vein thrombosis (DVT) and/or pulmonary em-
bolism (PE), is a relatively common cardiovascular dis-
order. Each year, approximately one to two cases per
1000 population present with acute symptomatic VTE
[1,2]. Standard therapy for these patients consists of
low-molecular-weight heparin combined with a vitamin
K antagonist (VKA) [3,4]. Several direct oral anticoagu-
lants have been evaluated recently for the acute and ex-
tended treatment of symptomatic VTE [5-10], and their
use could obviate the need for parenteral treatment and
laboratory monitoring of the anticoagulant effect.
Two studies, EINSTEIN-DVT and EINSTEIN-PE, com-
pared a single-drug approach using the oral, direct factor
Xa inhibitor rivaroxaban with standard-therapy consisting
of enoxaparin overlapping with and followed by a VKA for
the treatment of DVT and/or PE [8,9]. These studies
showed similar efficacy and a tendency towards a lower in-
cidence of major bleeding with rivaroxaban; the results
formed the basis for regulatory approval of rivaroxaban
for acute and extended treatment of DVT and/or PE [8,9].
Both studies used an identical design, treatment regi-
mens, outcome definitions, and adjudication processes
to allow for an a priori pooled analysis based on individ-
ual patient data. The aim of this analysis was to provide
more precise estimates of efficacy and safety, in particu-
lar the pattern of bleeding events. In addition, the ana-
lysis allowed more detailed investigation of the efficacy
and safety of rivaroxaban in key clinical subgroups in
which VKA therapy is associated with an increase in
complications, such as in patients who are elderly or
renally impaired, and in those with cancer [11-13].
Therefore, the current analysis focused on these groups
of patients and, in addition, analyzed the performance of
rivaroxaban in patients with previous VTE and in those
presenting with a large clot burden.
Methods
Patients
Patients were potentially eligible if they had symptom-
atic DVT and/or PE. The major ineligibility criteria
were: a therapeutic dose of low-molecular-weight hep-
arin, fondaparinux, or unfractionated heparin for more
than 48 hours; more than a single dose of a VKA; treat-
ment of the current episode with thrombectomy, a vena
cava filter, or fibrinolytic therapy; any contraindication
listed in the local labeling of enoxaparin, warfarin, or
acenocoumarol; or a creatinine clearance <30 ml/min.
Treatment regimens
Identical rivaroxaban and standard-therapy regimens
were evaluated in both trials. Patients assigned to
rivaroxaban were given 15 mg orally twice-daily for21 days, followed by 20 mg once-daily. Patients assigned
to standard-therapy received enoxaparin subcutaneously
at a dose of 1.0 mg/kg body weight twice-daily and
either oral warfarin or acenocoumarol (international
normalized ratio (INR), 2.0–3.0), started within 48 hours
after randomization. Patients were treated for 3, 6, or
12 months, as determined locally.
Follow-up and outcome assessment
Both studies used the same protocol to ascertain out-
comes. Patients were followed for the intended treatment
period and assessed at fixed intervals that were identical in
the two treatment groups [8,9]. The prespecified efficacy
outcome was symptomatic recurrent VTE, i.e. the com-
posite of fatal or nonfatal PE or DVT [8,9]. The pre-
specified principal safety outcome was clinically relevant
bleeding, defined as the composite of major and nonmajor
clinically relevant bleeding, as described previously [8,9].
Bleeding was defined as major if it was clinically overt and
associated with a decrease in hemoglobin level of ≥2.0 g/dl;
if bleeding led to the transfusion of ≥2 units of red cells;
or if bleeding was intracranial or retroperitoneal, occurred
in another critical site, or contributed to death. Nonmajor
clinically relevant bleeding was defined as overt bleeding
that did not meet the criteria for major bleeding but was
associated with medical intervention, unscheduled contact
with a physician, interruption or discontinuation of study
drug, or discomfort or impairment of activities of daily
life. We also prespecified to analyze net clinical benefit,
which was defined as the composite of the primary effi-
cacy outcome and major bleeding.
Key clinical subgroups
Efficacy and safety outcomes were separately analyzed
in key prespecified subgroups of patients, i.e. fragile pa-
tients, those with cancer, patients with a previous VTE,
and patients presenting with a large clot burden.
Fragility was defined as one or more of the following
criteria: age >75 years, calculated creatinine clearance
<50 ml/min, or low body weight (≤50 kg). The presence
of cancer was categorized as known active cancer at study
entry or cancer diagnosed during treatment. The extent of
DVT or PE was defined as (i) limited, if thrombosis
was not above the popliteal vein or PE was confirmed
to a single lobe involving ≤25% of the vasculature of
that lobe, or (ii) extensive, if thrombosis involved the
common femoral and/or iliac vein or if PE involved
multiple lobes and affected >25% of the entire pulmonary
vasculature. All other results for thrombosis and PE were
classified as intermediate.
Statistical analysis
The EINSTEIN-DVT and EINSTEIN-PE studies were
each designed to test the hypothesis that rivaroxaban
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was event-driven and required a number of events to
provide 90% power using a margin of 2.0 for the
upper limit of the 95% confidence interval (CI) for the
estimated hazard ratio, and a two-sided alpha of 0.05.
For the pooled analysis, the prespecified noninferiority
margin was 1.75 [14].
The primary efficacy analysis was performed on an
intention-to-treat basis with the use of a Cox propor-
tional hazards model stratified according to the qualify-
ing DVT or PE and the intended duration of treatment,
with adjustment for the presence or absence of active
cancer at baseline.
Homogeneity of the DVT and PE evaluations was tested
with the Gail–Simon test of qualitative interaction [15].
Weighted absolute risk differences and their CIs were cal-
culated using the Mantel–Haenszel asymptotic method
with the weights based upon sample sizes per stratum.
To compare the pattern of major bleeding, the first
event was categorized as (i) fatal, (ii) nonfatal, but in a
critical organ or site, or (iii) associated with a fall in
hemoglobin and/or need for transfusion. The mean time
during which the INR was in the therapeutic range was
calculated after the discontinuation of enoxaparin, with
correction for interruptions in the administration of
VKAs or the use of concomitant heparins.Results
Patients
Between March 2007 and March 2011, a total of 8282
patients were randomized at 314 sites in 38 countries;
4151 patients were assigned to receive rivaroxaban and
4131 were assigned to receive standard-therapy (Figure 1).4130 Were included in
the safety analysis
4150 Were included in the
intention-to-treat analysis




1 Was excluded due to
invalid informed consent




Figure 1 Enrolment and outcomes. VKA, Vitamin K antagonist.The characteristics of the patients in the treatment groups
were similar at baseline in both studies (Table 1) [8,9].Treatment and follow-up
In the standard-therapy group, the median duration of
enoxaparin treatment was 6 days (interquartile range,
4–9 days), and the INR at the end of enoxaparin treatment
was ≥2.0 in 82.2% of patients. The mean percentage of
time during which the INR was in the therapeutic range
(2.0–3.0) was 61.7%; the corresponding percentages for
an INR >3.0 and <2.0 were 16.0% and 22.3%, respect-
ively. In the rivaroxaban group, adherence to therapy
was ≥80% in 93.5% of patients. The mean duration of
study treatment was similar in both treatment arms
overall (207.6 ± 95.9 days in the rivaroxaban group and
204.0 ± 97.2 days in the standard-therapy group in the
intention-to-treat population) and in prespecified patient
subgroups (Table 2).Clinical outcomes
The primary efficacy outcome occurred in 86 (2.1%)
rivaroxaban patients compared with 95 (2.3%) standard-
therapy patients; hazard ratio, 0.89 (95% CI, 0.66 to
1.19); one-sided p < 0.001 for the noninferiority margin
of 1.75 and two-sided p = 0.41 for superiority; and abso-
lute risk reduction of 0.2% in favor of rivaroxaban (95%
CI, –0.4% to 0.9%) (Table 3; Figure 2). No heterogeneity
between the DVT and PE trial results was present (Gail–
Simon test of qualitative interaction, p = 0.29).
By day 21, at the end of twice-daily rivaroxaban ad-
ministration, the primary efficacy outcome had occurred
in 39 (0.9%) rivaroxaban patients and in 50 (1.2%)
standard-therapy patients.4131 Were included in the
intention-to-treat analysis
4131 Were assigned to
receive enoxaparin/VKA








Table 1 Demographic and clinical characteristics
EINSTEIN-DVT [8] EINSTEIN-PE [9] EINSTEIN pooled
Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA
(N = 1731) (N = 1718) (N = 2419) (N = 2413) (N = 4151) (N = 4131)
Male sex–n (%) 993 (57.4) 967 (56.3) 1309 (54.1) 1247 (51.7) 2302 (55.5) 2214 (53.6)
Mean age–years ± SD 55.8 ± 16.4 56.4 ± 16.3 57.9 ± 7.3 57.5 ± 7.2 57.0 ± 17.0 57.0 ± 16.8
Risk factor associated with VTE–n (%)
Recent surgery or trauma 338 (19.5) 335 (19.5) 415 (17.2) 398 (16.5) 753 (18.1) 733 (17.7)
Previous VTE 336 (19.4) 330 (19.2) 455 (18.8) 489 (20.3) 791 (19.1) 819 (19.8)
Active cancer 118 (6.8) 89 (5.2) 114 (4.7) 109 (4.5) 232 (5.6) 198 (4.8)
Estrogen therapy 140 (8.1) 115 (6.7) 207 (8.6) 223 (9.2) 347 (8.4) 338 (8.2)
Immobilization 265 (15.3) 260 (15.1) 384 (15.9) 380 (15.7) 649 (15.6) 640 (15.5)
Known thrombophilic condition 107 (6.2) 116 (6.8) 138 (5.7) 121 (5.0) 245 (5.9) 237 (5.7)
Unprovoked VTE 1055 (60.9) 1083 (63.0) 1566 (64.7) 1551 (64.3) 2621 (63.1) 2634 (63.8)
Duration of study treatment–days
(mean [SD])*
193.6 (89.3) 187.5 (92.5) 216.3 (98.7) 214.3 (98.9) 207.6 ± 95.9 203.8 ± 97.4
*Duration of actual study treatment after randomization until end of treatment (safety population).
SD Standard deviation, VKA Vitamin K antagonist, VTE Venous thromboembolism.
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major clinically relevant bleeding event, occurred in 388
(9.4%) rivaroxaban patients compared with 412 patients
(10.0%) in the standard-therapy group; hazard ratio, 0.93
(95% CI, 0.81 to 1.06) and absolute risk reduction, 0.6%
(95% CI, –0.7% to 1.9%; p = 0.27) (Table 3, Figure 2).
A first major bleeding was observed in 40 (1.0%)
rivaroxaban patients and in 72 (1.7%) standard-therapy
patients (hazard ratio, 0.54; 95% CI, 0.37 to 0.79; p = 0.002;
absolute risk reduction, 0.8% in favor of rivaroxaban; 95%
CI, 0.3% to 1.3%; p = 0.002). The difference was deter-
mined primarily by the reductions in the numbers of
intracranial (five vs. 13), retroperitoneal (one vs. eight)
(Table 3), and gastrointestinal (including rectal and anal)
bleeding events (15 vs. 26). By day 21, major bleeding had
occurred in 16 (0.4%) rivaroxaban patients and in 33
(0.8%) standard-therapy patients. The composite of recur-
rent VTE and major bleeding (net clinical benefit) was sig-
nificantly improved in patients treated with rivaroxaban,
occurring in 134 of 4150 patients in the rivaroxaban group
compared with 169 of 4131 patients in the standard-
therapy group (Table 2, hazard ratio, 0.77; 95% CI, 0.61
to 0.97).
Fragile patients
In total, 1573 patients (19.0%) were categorized as fragile
because of age (n = 1279), moderate or severe renal im-
pairment (n = 649), or low body weight (n = 107). Rates
of recurrent VTE were higher in fragile patients than in
nonfragile patients (rivaroxaban 2.7% vs. 1.9%; standard-
therapy 3.8% vs. 1.9%, respectively). In fragile and
nonfragile patients, the difference in recurrence rates be-
tween the rivaroxaban and standard-therapy groups wasnot statistically significant (Table 2). In contrast, a statis-
tically significant difference for major bleeding in favor
of rivaroxaban (1.3%) compared with standard-therapy
(4.5%) was observed in fragile patients (hazard ratio,
0.27; 95% CI, 0.13 to 0.54; absolute risk reduction, 3.2%;
95% CI 1.6% to 4.9%), whereas such differences were not
seen in nonfragile patients (0.9% vs. 1.1%; p = 0.01 for
interaction). The effects on recurrent VTE and bleeding
were consistent across the individual components that
defined the fragile population (Figure 3). In fragile pa-
tients, the net clinical benefit (hazard ratio, 0.51; 95% CI,
0.34 to 0.77) was statistically significantly more favorable
in rivaroxaban patients (Table 2).
Active cancer
A total of 430 patients (5.2%) had known active cancer
at baseline, whereas 167 patients (2.0%) were diagnosed
with cancer during the study. In those with cancer at
baseline, recurrent VTE was observed in six (2.6%)
of 232 rivaroxaban patients and in eight (4.0%) of
198 standard-therapy patients, whereas major bleeding
occurred in six (2.6%) of 232 rivaroxaban patients and
in eight (4.1%) of 196 standard-therapy patients.
Among the 167 patients diagnosed with cancer during
the study, recurrent VTE was diagnosed in 10 (11.9%) of
84 rivaroxaban patients and in 12 (14.5%) of 83 standard-
therapy patients. In this group, major bleeding occurred in
three (3.6%) and six (7.3%) patients, respectively.
In patients with cancer, recurrent VTE occurred in 16
(5.1%) of 316 rivaroxaban patients and in 20 (7.1%) of
281 standard-therapy patients (hazard ratio, 0.69; 95% CI,
0.36 to 1.33; absolute risk reduction, 2.0%; 95% CI –1.8%
to 5.8%). Of the 16 events in the rivaroxaban group,
Table 2 Efficacy and safety outcomes and net clinical benefit in all patients and selected patient subgroups
Mean duration of treatment Recurrent venous thromboembolism Nonmajor clinically relevant and
major bleeding
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40/4130 (1.0) 72/4116 (1.7) 0.54
(0.37–0.79)
134/4150 (3.2) 169/4131 (4.1) 0.77
(0.61–0.97)








10/788 (1.3) 35/779 (4.5) 0.27
(0.13–0.54)*
36/791 (4.6) 66/782 (8.4) 0.51
(0.34–0.77)†








30/3342 (0.9) 37/3337 (1.1) 0.80
(0.49–1.29)
98/3359 (2.9) 103/3349 (3.1) 0.93
(0.71–1.23)








9/316 (2.8) 14/278 (5.0) 0.53
(0.23–1.23)
26/316 (8.2) 37/281 (13.2) 0.60
(0.36–0.99)








31/3820 (0.8)‡ 58/3832 (1.5)‡ 0.53
(0.34–0.82)












7/788 (0.9) 14/813 (1.7) 0.51
(0.21–1.27)












33/3342 (1.0) 58/3303 (1.8) 0.54
(0.35–0.83)












8/796 (1.0) 11/813 (1.4) 0.75
(0.30–1.87)












20/1864 (1.1) 32/1876 (1.7) 0.62
(0.36–1.09)












11/1359 (0.8) 28/1326 (2.1) 0.36
(0.18–0.73)
48/1364 (3.5) 56/1327 (4.2) 0.81
(0.55–1.19)
*For major bleeding, the p-value for the treatment group × fragility interaction was 0.011, suggesting heterogeneity. †For net clinical benefit, the p-value for the treatment group × fragility interaction was 0.017.
‡In this analysis, six DVT patients were randomized to rivaroxaban but received comparator. §For recurrent VTE, the p-value for the treatment group × previous DVT/PE was 0.032. For all other outcomes and analyses
the interactions between treatment group and the subgroups of fragility [yes/no], baseline cancer [yes/no], previous DVT/PE [yes/no], clot burden for outcomes [limited/intermediate/extensive]), the pinteractions were
larger than 0.05 (nonsignificant) calculated by the corresponding Cox proportional hazards models. ¶In the clot burden analysis, a total of 71 patients in the rivaroxaban group and 68 patients in the enoxaparin/VKA
group had missing data. A further 43 and 40 patients in the rivaroxaban and enoxaparin/VKA groups, respectively, did not have confirmed DVT and PE.
















Table 3 Clinical outcomes
EINSTEIN-DVT EINSTEIN-PE EINSTEIN pooled
Outcome Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA
Efficacy
Intention-to-treat population–N 1731 1718 2419 2413 4150 4131
First recurrent VTE–n (%) 36 (2.1) 51 (3.0) 50 (2.1) 44 (1.8) 86 (2.1) 95 (2.3)
Fatal PE 0 0 2 1 2 (<0.1) 1 (<0.1)
Death (PE cannot be excluded) 2 6 8 5 10 (0.2) 11 (0.3)
DVT and PE 1 0 0 2 1 (<0.1) 2 (<0.1)
DVT only 14 28 18 17 32 (0.8) 45 (1.1)
PE only 19 17 22 19 41 (1.0) 36 (0.9)
Death from any cause–n (%) 38 (2.2) 49 (2.9) 58 (2.4) 50 (2.1) 96 (2.3) 99 (2.4)
PE/PE not ruled out 4 6 11 7 15 (0.4) 13 (0.3)
Bleeding 1 5 5 4 6 (0.1) 9 (0.2)
Cardiovascular 2 4 10 3 12 (0.3) 7 (0.2)
Other 31 34 32 36 63 (1.5) 70 (1.7)
Safety
N 1718 1711 2412 2405 4130 4116
First major plus nonmajor clinically
relevant bleeding event–n (%)
139 (8.1) 138 (8.1) 249 (10.3) 274 (11.4) 388 (9.4) 412 (10.0)
First major bleeding event–n (%)
Any 14 (0.8) 20 (1.2) 26 (1.1) 52 (2.2) 40 (1.0) 72 (1.7)
Fatal bleeding 1 (<0.1) 5 (0.3) 2 (<0.1) 3 (0.1) 3 (<0.1) 8 (0.2)
Retroperitoneal 0 0 0 1 (<0.1) 0 1 (<0.1)
Intracranial 0 2 (0.1) 2 (<0.1) 2 (<0.1) 2 (<0.1) 4 (<0.1)
GI/thorax 1 (<0.1) 3 (0.2) 0 0 1 (<0.1) 3 (<0.1)
Nonfatal in a critical site* 3 (0.2) 3 (0.2) 7 (0.3) 24 (1.0) 10 (0.2) 27 (0.7)
Retroperitoneal 0 1 (<0.1) 1 (<0.1) 6 (0.2) 1 (<0.1) 7 (0.2)
Intracranial 2 (0.1) 0 1 (<0.1) 9 (0.4) 3 (<0.1) 9 (0.2)
Intraocular 1 (<0.1) 1 (<0.1) 2 (<0.1) 2 (<0.1) 3 (<0.1) 3 (<0.1)
Pericardial 0 0 0 2 (<0.1) 0 2 (<0.1)
Intra-articular 0 1 (<0.1) 0 3 (0.1) 0 4 (<0.1)
Adrenal/pulmonary/abdominal 0 0 3 (<0.1) 2 (<0.1) 3 (<0.1) 2 (<0.1)
Nonfatal, noncritical site but associated
with a fall in hemoglobin ≥2 g/dl and/or
transfusions ≥2 units
10 (0.6) 12 (0.7) 17 (0.7) 25 (1.0) 27 (0.7) 37 (0.9)
Nonmajor clinically relevant bleeding–n (%)† 126 (7.3) 119 (7.0) 228 (9.5) 227 (9.4) 354 (8.6) 346 (8.4)
*Columns may fail to sum because of additional bleeding events at other sites. †Refers to all nonmajor clinically relevant bleeding events, not just the first event.
DVT Deep-vein thrombosis, GI Gastrointestinal, PE Pulmonary embolism, VKA Vitamin K antagonist, VTE Venous thromboembolism.
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ment; the corresponding numbers in the standard-therapy
group were 20 and 16 events. Major bleeding occurred in
nine patients (2.8%) and in 14 patients (5.0%), respectively
(hazard ratio, 0.53; 95% CI, 0.23 to 1.23; absolute risk
reduction, 2.2%; 95% CI, –1.0 to 5.4%). In patients with
cancer, the net clinical benefit (hazard ratio, 0.60; 95% CI,
0.36 to 0.99) was statistically significantly more favorable
in rivaroxaban patients (Table 2).Extent of deep-vein thrombosis and pulmonary embolism
at study entry
Among patients with limited thrombosis, recurrent VTE
occurred in 10 (1.3%) of 799 rivaroxaban patients com-
pared with 19 (2.3%) of 815 standard-therapy patients.
In those with an intermediate clot burden, these inci-
dences were 2.2% (41 of 1873) and 2.6% (49 of 1881), re-
spectively. In patients with extensive clots, recurrent
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4130 3768 3671 3406 3270 3210 1928 1051 1009 936 878 853 453
4116 3738 3618 3330 3186 3125 1711 1025 981 907 857 823 369
4150 4018 3969 3924 3604 3579 3283 1237 1163 1148 1102 1034 938
4131 3932 3876 3826 3523 3504 3236 1215 1149 1109 1071 1019 939
Figure 2 Kaplan–Meier curves. a. Primary efficacy outcome, b. Principal safety outcome and c. Major bleeding. VKA, Vitamin K antagonist.
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Rivaroxaban Enoxaparin/VKA  HR (95% CI) 




Nonfragile 65/3359 1.9 65/3349 1.9 
8.3287/037.2197/12eligarF
Age >75 years 15/656 2.3 23/627 3.7 
Creatinine clearance 
<50 ml/min 
11/332 3.3 11/322 3.4 
Body weight <50 kg 3/42 7.1 2/66 3.0 
0.1 1 10 100









Nonfragile 30/3342 0.9 37/3337 1.1 
5.4977/533.1887/01eligarF
Age >75 years 8/655 1.2 28/624 4.5 
Creatinine clearance 
<50 ml/min 
3/329 0.9 13/320 4.1 
Body weight <50 kg 0/42 0.0 3/65 4.6 Nonestimable
0.01 0.1 1 10
Figure 3 Efficacy and safety outcomes in fragile patients and subgroups. a. Primary efficacy. b. Major bleeding. CI, Confidence interval;
HR, Hazard ratio; VKA, Vitamin K antagonist.
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patients (Table 2).
Previous venous thromboembolism
Of the 1610 patients who had a previous venous
thromboembolic event at study entry, 11 of 791 patients
(1.4%) in the rivaroxaban group and 25 of 819 patients
(3.1%) in the standard-therapy group developed a
recurrent venous thromboembolic event (hazard ratio,0.45; 95% CI, 0.22 to 0.91). This compared with 75 of
3359 patients (2.2%) in the rivaroxaban group and 70
of 3312 patients (2.1%) in the standard-therapy group
who presented with a first episode of VTE (hazard
ratio, 1.04; 95% CI, 0.75 to 1.45). In patients with
previous VTE, the net clinical benefit (hazard ratio,
0.52; 95% CI, 0.31 to 0.90) was statistically significantly
more favorable in patients treated with rivaroxaban
(Table 2).
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This prespecified pooled analysis of two large, random-
ized studies evaluated the efficacy and safety of a single-
drug approach with oral, fixed-dose rivaroxaban versus
the combination of subcutaneous enoxaparin and INR-
titrated VKA therapy in patients with acute symptomatic
VTE. We found that rivaroxaban had similar efficacy as
standard-therapy and was associated with a significantly
lower rate of major bleeding. Efficacy and safety results
were consistent among key patient subgroups. Overall,
the rates of recurrent VTE and major bleeding were low
in the standard-therapy group and were similar to those
in contemporary clinical studies [5,10,16,17].
Some limitations of our study should be noted. Firstly,
we used an open-label design that could have biased as-
sessment of outcomes. Nevertheless, efforts were made
to limit investigator bias, including the requirement to
use objective and validated tests to confirm suspected
recurrent VTE and the use of an independent commit-
tee, whose members were blinded to treatment assign-
ment, to adjudicate outcome events. Secondly, in the
standard-therapy arm the choice of VKA was limited to
acenocoumarol and warfarin, which might not have been
the VKA of choice for some participating centers. How-
ever, INR monitoring was intensive and required assess-
ment at least once a month. The time patients spent in
the target therapeutic range (INR, 2.0–3.0) was in line
with that achieved in contemporary studies [18]. There-
fore, we believe the results obtained in this large, global
study, with limited exclusion criteria, are valid and can
be generalized to typical patients with DVT and/or PE.
Pooling the results of EINSTEIN-DVT and EINSTEIN-
PE enabled us to derive clinically relevant results for im-
portant subgroups of patients. Large clots and a history of
(multiple episodes of) VTE are conditions that are of spe-
cial concern to clinicians. Here, the efficacy of rivaroxaban
was similar in patients presenting with small, intermediate,
or extensive DVT or PE and was similar to standard-
therapy. Likewise, the efficacy of rivaroxaban was simi-
lar both in patients presenting with a first episode of
VTE and in those with a history of one or more epi-
sodes of VTE.
Bleeding is the most common complication of anti-
coagulant treatment; in this analysis, it occurred as often
in patients receiving rivaroxaban as in patients receiving
standard-therapy. However, major bleeding, the most
worrying complication, was statistically significantly less
frequent in patients treated with rivaroxaban. This re-
duction was seen mainly in fatal and nonfatal critical-
site bleeding, such as intracranial and retroperitoneal
bleeding. It is well known that VKA therapy is a chal-
lenge in patients who are elderly, have impaired renal
function, are frail, or have cancer. Particularly in these
patients, rivaroxaban yielded favorable clinical results.In fragile patients, the incidence of major bleeding was
reduced from 4.5% with standard-therapy to 1.3% with
rivaroxaban. This translates into averting one major
bleeding event for every 31 fragile patients treated with
rivaroxaban rather than standard-therapy, and the risk
of recurrent VTE remained similar. In patients with
cancer, the incidence of both bleeding and recurrent
VTE tended to be lower, resulting in a favorable benefit–
risk profile. However, selective inclusion of patients
with cancer might have occurred: patients with a life
expectancy of <3 months were excluded, and, according to
guidelines, long-term subcutaneous low-molecular-weight
heparin is the treatment of choice for patients with VTE
and cancer [19]. In addition, patients diagnosed with
cancer after randomization were retrospectively reclassi-
fied to the cancer group. However, unless rivaroxaban or
standard-therapy could have differential effects on a new
diagnosis of cancer during the trial, the principle of
randomization was maintained using an intention-to-treat
approach to the analysis. Therefore, we believe that in pa-
tients with cancer who develop VTE, rivaroxaban may be
considered as an alternative in those cases in which the at-
tending physician would have given standard-therapy ra-
ther than long-term low-molecular-weight heparin. Based
on the observed results in patients with cancer, a head-to-
head comparison of rivaroxaban with long-term low-
molecular-weight heparin seems warranted.
Conclusions
The prespecified, individual, patient data meta-analysis
presented here included more than 8000 patients and
shows that rivaroxaban can be used as a single-drug ap-
proach for the treatment of acute symptomatic DVT
and/or PE. Particularly in those patients in whom VKA
therapy is associated with an increase in complications,
use of rivaroxaban resulted in an important safety
advantage.
Appendix
Members of the EINSTEIN Investigators are listed in the
supplementary information (Additional file 1).
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Additional file 1: Members of the EINSTEIN Investigators.
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